novavax covid vaccine

Order byBest matchMost fresh

FDA approves Novavax's Covid-19 vaccine

Top News

Overview

Impacts

Healthy Returns: Novavax scores narrower Covid vaccine approval after delay

Novavax can finally breathe a sigh of relief – at least a small one. The Food and Drug Administration approved the company's Covid-19 vaccine after more than a month of delay b

· 1d · on MSN

Clinical Advisor · 13h

FDA Approves Novavax’s COVID-19 Vaccine Nuvaxovid

· 4d · on MSN

After delay, FDA approves Novavax’s Covid-19 vaccine, but only for older people and those at high risk

F.D.A. Poised to Restrict Access to Covid Vaccines

The Food and Drug Administration will permit Covid vaccines for adults over 65 and those with certain medical conditions in the fall, according to new regulatory standards detailed on Tuesday by agen...

· 1d

FDA tightens requirements for COVID vaccine, adding trials for healthy adults

· 1d

Annual COVID-19 Shots For Healthy Younger Adults, Children Will No Longer Be Routinely Approved

FDA may limit future Covid-19 shots to older people and those at risk of serious infection

Millions of healthy adults and kids will likely lose access to updated vaccines under the new criteria.

· 1d

· 12h

FDA plans to limit COVID vaccine to only high-risk people. Who would still be eligible?

· 1d

FDA sets new COVID booster guidelines for healthy adults under 65

14hon MSN

Who can get updated COVID vaccines this fall? FDA will OK for high-risk groups, calls for new clinical trials

The Food and Drug Administration says it has decided to continue approving COVID-19 vaccine updates for seniors and others at higher risk of severe disease, but will require vaccine makers to conduct major new clinical trials before approving them for wider use.

14hon MSN

FDA’s new approach raises questions about fall COVID vaccine availability

Health experts say there are legitimate questions about how much everyone still benefits from yearly COVID vaccination or whether they should be recommended only for people at increased risk.

Novavax (NasdaqGS:NVAX) Reports Q1 2025 Financial Turnaround

Novavax (NasdaqGS:NVAX) recently reported a significant financial turnaround for Q1 2025, demonstrating substantial revenue growth and net income improvements. The amending of its collaboration agreement with Takeda offers increased flexibility in vaccine development,